RT Journal
A1 Pletcher MJ, Tice JA, Pignone M
T1 MOdeling cardiovascular disease prevention
JF JAMA
JO JAMA
YR 2010
FD March 3
VO 303
IS 9
SP 835
OP 835
DO 10.1001/jama.2010.188
UL http://dx.doi.org/10.1001/jama.2010.188
AB 
To the Editor: In their Commentary, Drs Hingorani and Psaty1 invoked the prevention paradox (a large proportion of cardiovascular disease [CVD] events occur among the many individuals with average risk factor values) in their discussion of whether to embrace new CVD risk markers as tools for targeting or personalizing statin therapy. They also described another well-known apparent paradox: even risk markers that are strongly associated with the outcome of interest (relative risks of 3 to 5 or even larger) often seem to contribute little in terms of discrimination or reclassification.2